This stands in contrast to an analysis by the NHLBI TOPMed Lipids Working Group, who reported a ~30 mg dl^-1 effect size for both a pathogenic variant in a Mendelian hypercholesterolemia gene (LDLR, APOB, PCSK9, ABCG5, ABCG8, and LDLRAP1) and an extreme PGSLDL-C ( > 95th percentile) in European Americans29. The gene discussed is LDLRAP1; the disease is familial hypercholesterolemia.